U.C.A. AG

M&A Activity • Oct 8, 2001

News Details

Corporate | 8 October 2001 20:15

U.C.A. AG english

Corpoprate-news transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Trade sale of the 50 % investment in the BioMed Venture AG Strategic termination of the business sector Biotech/Life Science Concentration on the area of high tech engineering October 8th, 2001, Munich U.C.A. is selling its 50 % share in the BioMed Venture AG to the “Kreissparkasse” in Hanover, one of the large institutes within the association of savings banks. In the future, U.C.A. will no longer directly invest in Biotech- and Life Science start-ups. With this step, U.C.A. consciously pulls out of financing fledgling companies in this sector because it appears to make sense for U.C.A. that large financial groups and industrial partners assume this role due to the long development cycles and corresponding high prefinancing payments. The increased concentration on investment areas such as micro systems technology, nano technology, sensory analysis and optoelectronics, classical German high tech engineering sectors with intelligible finance requirements in time periods which can be planned is U.C.A.’s answer to the increasing demand for promising investments in the VC area. With 10 investments, U.C.A. is already represented in these areas. The Managing Board Contact: Investor Relations Daniel Schirok Tel. : + 49 (0) 89 – 99 31 94-36 e-mail : investor.relations@uca.de end of announcement (c)DGAP 08.10.2001 ——————————————————————————– WKN: 701200; Index: Listed: Freiverkehr in Berlin, Düsseldorf, Frankfurt, Hamburg, München (Prädikatsmarkt) und Stuttgart 082015 Okt 01